Pharmaceutical Technology on MSN4d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
Nature1mon
Critical illness polyneuropathy and myopathy in the intensive care unit
Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) are major complications that occur in severely ill patients who require intensive care treatment. CIP and CIM affect the ...
Baylor College of Medicine4y
Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...
PMLive1d
AstraZeneca/Ionis’ Wainzua granted EC approval to treat rare disease ATTRv-PN
AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...
pharmaphorum5d
EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy
AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated ...
Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S‑1117, a Novel Pan‑IgG Protease Therapy for Antibody-Mediated Diseases
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...
Business Wire5d
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
“Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent ...
2025 Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report Envisions the Future of CIDP Treatments
The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...
Ionis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatment
Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...
Medical Dialogues3d
AstraZeneca-Ionis Pharma Wainzua approved in EU for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...